Home Stock

Stock Research: Embla Medical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Embla Medical

CPH:EMBLA IS0000000040
74
  • Value
    32
  • Growth
    89
  • Safety
    Safety
    82
  • Combined
    84
  • Sentiment
    36
  • 360° View
    360° View
    74
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Embla Medical hf, formerly Ossur hf, develops and distributes medical equipment and supplies. It operates in non-invasive prosthetics, medical braces, and supports. Based in Iceland, they have clinics worldwide. In the last fiscal year, the company had a market cap of $2,161 million, profits of $535 million, and revenue of $855 million, with 4078 employees.

more

ANALYSIS: With an Obermatt 360° View of 74 (better than 74% compared with alternatives), overall professional sentiment and financial characteristics for the stock Embla Medical are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Embla Medical. The consolidated Growth Rank has a good rank of 89, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 89% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 82 which means that the company has a financing structure that is safer than 82% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 32 which means that the share price of Embla Medical is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 68% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 36, which means that professional investors are more pessimistic about the stock than for 64% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Capital Growth
Country Iceland
Industry Health Care Equipment
Size Medium
Website emblamedical.com
Index
Embla Medical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
32 30 43 45
Growth
89 68 69 87
Safety
Safety
82 38 16 15
Sentiment
36 50 61 48
360° View
360° View
74 35 44 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
24 67 40 81
Opinions Change
50 8 50 50
Pro Holdings
n/a 6 6 6
Market Pulse
26 85 88 56
Sentiment
36 50 61 48
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
32 30 43 45
Growth
89 68 69 87
Safety Safety
82 38 16 15
Combined
84 24 25 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
59 49 56 55
Price vs. Earnings (P/E)
26 42 44 35
Price vs. Book (P/B)
61 54 58 50
Dividend Yield
1 1 1 1
Value
32 30 43 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
52 64 56 52
Profit Growth
78 54 80 100
Capital Growth
90 76 67 98
Stock Returns
39 56 39 29
Growth
89 68 69 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
47 32 32 28
Refinancing
67 43 37 31
Liquidity
81 48 31 28
Safety Safety
82 38 16 15

Similar Stocks

Discover high‑ranked alternatives to Embla Medical and broaden your portfolio horizons.

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: XX-Large
Full Stock Analysis

Volkswagen VW

GER:VOW
Country: Germany
Industry: Automobile Manufacturers
Size: XX-Large
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Hornbach Holding

GER:HBH
Country: Germany
Industry: Home Improvement Retail
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews